APHINITY 6-year data: Benefit ongoing in HER2+ early BC, no significant OS benefitDecember 12, 2019Breast Cancer
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCLDecember 12, 2019Lymphoma & Plasma Cell Disorders
Tucatinib called game-changer in HER2-positive metastatic breast cancerDecember 12, 2019Breast Cancer
Trastuzumab deruxtecan has good activity in advanced HER2-positive breast cancerDecember 12, 2019Breast Cancer
New evidence further supports starting CRC screening at age 45December 10, 2019GastroenterologyPreventive CareGastrointestinal Cancer
Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLLDecember 10, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
